Zacks: Analysts Anticipate KITOV PHARMA LT/S (KTOV) to Announce -$0.01 EPS
Wall Street brokerages forecast that KITOV PHARMA LT/S (NASDAQ:KTOV) will announce earnings of ($0.01) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for KITOV PHARMA LT/S’s earnings. The company is expected to report its next earnings results on Monday, January 1st.
On average, analysts expect that KITOV PHARMA LT/S will report full-year earnings of ($0.03) per share for the current year. For the next year, analysts expect that the firm will post earnings of ($0.02) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for KITOV PHARMA LT/S.
Several equities analysts have commented on the stock. Zacks Investment Research raised shares of KITOV PHARMA LT/S from a “sell” rating to a “hold” rating in a research report on Friday, June 15th. HC Wainwright reissued a “buy” rating and set a $12.50 target price on shares of KITOV PHARMA LT/S in a research report on Tuesday, June 19th.
KITOV PHARMA LT/S Company Profile
Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.
See Also: Asset Allocation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KITOV PHARMA LT/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KITOV PHARMA LT/S and related companies with MarketBeat.com's FREE daily email newsletter.